Alladapt Immunotherapeutics is a private clinical-stage biopharmaceutical developing ADP101, an investigational oral immunotherapy representing the nine food groups responsible for most significant food-allergic reactions. The company is conducting the Harmony Phase 1/2 randomized, double-blind, placebo-controlled study and an Encore open-label extension. ADP101 is being advanced toward a potential Phase 3 pivotal trial and Alladapt is completing a manufacturing facility intended for late-stage clinical supply and potential commercial product. Recent financing activity — an oversubscribed $119 million institutional financing plus the new term loan — extends the company’s cash runway into 2024. The company was co-founded in 2018 and is based in Menlo Park, California. Alladapt is a private, clinical-stage biopharmaceutical company developing prescription therapeutics to treat IgE-mediated food allergy. Its lead candidate, ADP101, is an investigational oral immunotherapy representing the nine food groups responsible for the vast majority of significant food-allergic reactions globally and is being studied in the Harmony Phase 1/2 trial and the Encore open-label extension. The company plans to prepare for a potential pivotal trial while continuing to build out its manufacturing facility and expand its pipeline. Proceeds from the financing will fund ongoing clinical development of ADP101, manufacturing buildout, and further pipeline expansion. Alladapt was co-founded in 2018 by Ashley Dombkowski, Ph.D., and Kari Nadeau, M.D., Ph.D., and is based in Menlo Park, California. Alladapt Immunotherapeutics is a privately held biopharmaceutical company focused on developing prescription therapeutics to address food allergy. Its lead program, ADP101, is a proprietary broad‑spectrum oral immunotherapy being advanced to mitigate food allergy triggered by single or multiple proteins from a wide-ranging set of common allergens. The company announced plans to initiate a clinical trial later in 2020 and will use financing proceeds to support the initial clinical development of ADP101. Alladapt emphasizes incorporating patient perspectives in product formulation and clinical development. The company was co-founded by Kari Nadeau, MD, PhD (scientific inventor) and Ashley Dombkowski, PhD (CEO), and lists Dana McClintock, MD as Chief Medical Officer and a distinguished scientific advisory board. Financially, Alladapt completed a $60 million Series C in February 2020 to fund its clinical advancement.

Total raised

$229M

Funding rounds

3

Latest round

Debt Financing

Latest activity

Aug 2022